
CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | |
| S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | |
| 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | |
| 4 Filing | 2026-01-26 | English | |
| 4 Filing | 2026-01-05 | English | |
| 4 Filing | 2026-01-05 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 39639190 | S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | ||
| 34662842 | S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | ||
| 32880286 | 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | ||
| 18269065 | 4 Filing | 2026-01-26 | English | ||
| 18269090 | 4 Filing | 2026-01-05 | English | ||
| 18269058 | 4 Filing | 2026-01-05 | English | ||
| 18269037 | 4 Filing | 2026-01-05 | English | ||
|
2025
8 filings
| |||||
| 18269100 | 10-K Filing | 2025-12-29 | English | ||
| 9417629 | PRIMARY DOCUMENT | 2025-12-05 | English | ||
| 9417630 | Regulatory Filings 2025 | 2025-12-04 | English | ||
| 9417631 | FORM 8-K | 2025-11-24 | English | ||
| 9417632 | FORM S-3 | 2025-11-07 | English | ||
| 9417635 | FORM 8-K | 2025-11-05 | English | ||
| 9417633 | PRIMARY DOCUMENT | 2025-10-02 | English | ||
| 9417634 | PRIMARY DOCUMENT | 2025-10-02 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
E-Novia
A venture studio and consultancy that transforms Physical A…
|
E9IA | IT | Professional, scientific and te… |
|
Ensysce Biosciences, Inc.
Clinical-stage pharma firm developing abuse-deterrent drugs…
|
ENSC | US | Professional, scientific and te… |
|
Entheon Biomedical Corp.
Developing proprietary psychedelic medicines, specifically …
|
ENBI | CA | Professional, scientific and te… |
|
ENTROPY NEURODYNAMICS LIMITED
Develops computational tools and entropy-based metrics to a…
|
ENP | AU | Professional, scientific and te… |
|
Enveric Biosciences, Inc.
Develops novel small-molecule therapeutics for neuropsychia…
|
ENVB | US | Professional, scientific and te… |
|
ENVIRONMENTAL CLEAN TECHNOLOGIES LIMITED.
Develops low-emission technologies for energy, steelmaking,…
|
ECT | AU | Professional, scientific and te… |
|
Eone Diagnomics Genome Center Co., Ltd.
A healthcare company specializing in genetic analysis for p…
|
245620 | KR | Professional, scientific and te… |
|
Epi Biotech Co., Ltd.
Develops hair loss therapies and provides preclinical CRO s…
|
446440 | KR | Professional, scientific and te… |
|
Equillium, Inc.
Clinical-stage biotech developing therapies for autoimmune …
|
EQ | US | Professional, scientific and te… |
|
Eurofins-Cerep
Contract research organization for pre-clinical in vitro dr…
|
ALECR | FR | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.